Why is Glenmark Pharma falling/rising?

As of 02-Sep, Glenmark Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at 1,918.20, which reflects a decrease of 10.0 points or 0.52%. The stock has underperformed its sector today by 0.45%, and its delivery volume has significantly dropped by 30.83% compared to the 5-day average, indicating falling investor participation. Despite this recent downturn, the stock has shown strong performance over the longer term, with a year-to-date return of 19.23% and a remarkable 418.85% increase over the past three years. The company maintains a low Debt to EBITDA ratio of 1.00 times, suggesting a strong ability to service debt, and has high institutional holdings at 38.3%, which may provide stability and confidence in its fundamentals.
In the broader market context, Glenmark's short-term performance has been weaker than the benchmark, with a 1-week return of -1.54% compared to the Sensex's -0.78%. Over the past month, Glenmark has also underperformed, with a decline of 7.20% against a slight drop of 0.55% for the benchmark. This underperformance in the short term, coupled with reduced trading activity, may contribute to the stock's current price movement. However, the company's consistent returns over the last three years and its ability to outperform the BSE500 in annual periods suggest that it has the potential for recovery in the longer term.